Kyntra Bio Inc (KYNB) Stock Price, Quote & News

Company Profile

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 978 1200

Fax: 415 978 1902

Website: www.kyntrabio.com

Address:

350 Bay Street, Suite 100 #6009, San Francisco, United States

ARKADIY_PAROVOZOV Aug. 19 at 11:34 AM

$KYNB New meta-analysis (36 RCTs, ~27,700 patients) on HIF-PHIs including roxadustat in CKD anemia: significant reduction in RBC transfusions (RR 0.74) and rescue transfusions, with no increase in major CV events or mortality. Supports the class as an effective oral option. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1916346/abstract

0 · Reply

ARKADIY_PAROVOZOV Aug. 18 at 9:50 AM

$KYNB Latest 13F data on KYNB institutional holders: A few small new positions appeared (including GSA Capital with ~15.7k shares), while the main long-term holders (Armistice, Vanguard, Acadian, BlackRock, HighTower etc.) remain largely unchanged. https://fintel.io/sob/us/kynb

1 · Reply

MaxMiamiFl Aug. 16 at 9:48 PM

$KYNB is this crap ever going to recover.....or at least close to it.

0 · Reply

Estimize Aug. 13 at 3:01 PM

$KYNB reports after the close, Estimize Consensus +0.24 EPS and -0.10M Revs compared to WS http://www.estimize.com/kynb/fq2-2026?utm_conten

0 · Reply

ARKADIY_PAROVOZOV Aug. 13 at 1:29 PM

$KYNB Kyntra Bio reports Q2 2026 financial results today (August 13) after market close, followed by a conference call at 5:00 PM ET. Looking forward to any updates on the Phase 3 roxadustat protocol and FG-3246 progress.

1 · Reply

ARKADIY_PAROVOZOV Aug. 12 at 9:38 AM

$KYNB New real-world study published in Clinical and Experimental Nephrology (Aug 2026): Roxadustat was associated with a significantly lower incidence of peritoneal dialysis-associated peritonitis compared to rhuEPO (adjusted IRR 0.494, p=0.041). Suggests possible protective effects of HIF stabilization beyond anemia correction. Positive safety signal in PD patients. https://link.springer.com/article/10.1007/s10157-026-02926-6

0 · Reply

ARKADIY_PAROVOZOV Aug. 12 at 9:38 AM

$KYNB New paper in Frontiers in Cell and Developmental Biology (Aug 2026) discusses hypoxia-driven cardiac fibrosis after myocardial infarction. Roxadustat is mentioned positively for enhancing HIF signaling, promoting reparative M2 macrophage polarization, and potentially attenuating adverse cardiac remodeling. Interesting additional biological context for the HIF-PHI class beyond anemia. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2026.1814166/full

0 · Reply

Estimize Aug. 11 at 10:06 PM

Wall St is expecting -3.18 EPS for $KYNB Q2 [Reporting 08/13 AMC] http://www.estimize.com/intro/kynb?chart=historical&metric_name=eps&utm_c

0 · Reply

Estimize Aug. 11 at 8:03 PM

Wall St is expecting -3.33 EPS for $KYNB Q3 [Reporting 11/09 AMC] http://www.estimize.com/intro/kynb?chart=historical&metric_name=eps&utm_c

0 · Reply

ARKADIY_PAROVOZOV Aug. 11 at 2:57 PM

$KYNB New market analysis projects the Roxadustat market to reach $9.56 billion by 2030 (CAGR 6.9%), driven by rising anemia prevalence, preference for oral therapies, and growing adoption of HIF-PHIs in CKD. https://www.openpr.com/news/4597106/analysis-of-key-market-segments-driving-the-roxadustat-market

0 · Reply

Kyntra Bio Earnings Call Transcript: Q2 2026

Aug 13, 2026, 5:00 PM EDT - 5 days ago

Kyntra Bio Earnings release: Q2 2026

Aug 13, 2026, 5:00 PM EDT - 5 days ago

Kyntra Bio Quarterly report: Q2 2026

Aug 13, 2026, 5:00 PM EDT - 5 days ago

Kyntra Bio Slides: Q2 2026

Aug 13, 2026, 4:02 PM EDT - 5 days ago

Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Jun 12, 2026, 11:00 AM EDT - 2 months ago

Kyntra Bio Transcript: AGM 2026

Jun 11, 2026, 4:05 PM EDT - 2 months ago

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes

May 11, 2026, 5:00 PM EDT - 3 months ago

Kyntra Bio Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

Kyntra Bio Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

Kyntra Bio Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

Kyntra Bio Quarterly report: Q1 2026

May 11, 2026, 4:05 PM EDT - 3 months ago

Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

May 4, 2026, 4:05 PM EDT - 3 months ago

Kyntra Bio to Report First Quarter 2026 Financial Results

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Kyntra Bio Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Kyntra Bio Proxy statement: Proxy filing

Apr 13, 2026, 1:30 PM EDT - 4 months ago

Kyntra Bio Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 4:05 PM EDT - 4 months ago

Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference

Mar 16, 2026, 5:00 PM EDT - 5 months ago

Kyntra Bio Earnings Call Transcript: Q4 2025

Mar 16, 2026, 5:00 PM EDT - 5 months ago

Kyntra Bio Annual report: Q4 2025

Mar 16, 2026, 5:00 PM EDT - 5 months ago

Kyntra Bio Earnings release: Q4 2025

Mar 16, 2026, 5:00 PM EDT - 5 months ago

Kyntra Bio Slides: Q4 2025

Mar 16, 2026, 4:02 PM EDT - 5 months ago

Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 11, 2026, 2:20 PM EDT - 5 months ago

Kyntra Bio Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 7:00 AM EDT - 5 months ago

Kyntra Bio Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 5 months ago

Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 2:40 PM EST - 6 months ago

Kyntra Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 23, 2026, 5:10 PM EST - 6 months ago

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

Feb 17, 2026, 4:05 PM EST - 6 months ago

Kyntra Bio to Participate in Upcoming Investor Conferences

Jan 7, 2026, 7:30 AM EST - 8 months ago

FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum

Nov 10, 2025, 5:00 PM EST - 10 months ago

Kyntra Bio Earnings Call Transcript: Q3 2025

Nov 10, 2025, 5:00 PM EST - 10 months ago

Kyntra Bio Quarterly report: Q3 2025

Nov 10, 2025, 5:00 PM EST - 10 months ago

Kyntra Bio Earnings release: Q3 2025

Nov 10, 2025, 5:00 PM EST - 10 months ago

Kyntra Bio Slides: Q3 2025

Nov 3, 2025, 4:02 PM EST - 10 months ago

FibroGen to Report Third Quarter 2025 Financial Results

Sep 24, 2025, 7:00 AM EDT - 11 months ago

FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

Sep 9, 2025, 12:00 PM EDT - 1 year ago

Kyntra Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 4:02 PM EDT - 1 year ago

FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 18, 2025, 7:00 AM EDT - 1 year ago

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

Aug 11, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings Call Transcript: Q2 2025

Aug 11, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Quarterly report: Q2 2025

Aug 11, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings release: Q2 2025

Aug 11, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Slides: Q2 2025

Aug 11, 2025, 4:02 PM EDT - 1 year ago

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 4, 2025, 4:02 PM EDT - 1 year ago

FibroGen to Report Second Quarter 2025 Financial Results

Jun 12, 2025, 4:02 PM EDT - 1 year ago

FibroGen Announces 1-for-25 Reverse Stock Split

Jun 9, 2025, 4:02 PM EDT - 1 year ago

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

May 12, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings Call Transcript: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Quarterly report: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings release: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Slides: Q1 2025

May 12, 2025, 4:02 PM EDT - 1 year ago

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:24 AM EDT - 1 year ago

Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)

May 5, 2025, 4:05 PM EDT - 1 year ago

FibroGen to Report First Quarter 2025 Financial Results

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Kyntra Bio Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Kyntra Bio Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Kyntra Bio Proxy statement: Proxy Filing

Apr 2, 2025, 4:05 PM EDT - 1 year ago

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings Call Transcript: Q4 2024

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Annual report: Q4 2024

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings release: Q4 2024

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Slides: Q4 2024

Mar 17, 2025, 4:05 PM EDT - 1 year ago

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 4:45 PM EST - 1 year ago

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

Feb 20, 2025, 8:30 AM EST - 1 year ago

Kyntra Bio Transcript: Status Update

Feb 20, 2025, 8:30 AM EST - 1 year ago

Kyntra Bio Press release: Status Update

Feb 20, 2025, 8:30 AM EST - 1 year ago

Kyntra Bio Slides: Status Update

Feb 20, 2025, 6:40 AM EST - 1 year ago

FibroGen sells China unit to AstraZeneca in deal worth $160 million

AZN

Feb 20, 2025, 6:30 AM EST - 1 year ago

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

Dec 16, 2024, 8:05 AM EST - 1 year ago

FibroGen Appoints David DeLucia as Chief Financial Officer

Nov 12, 2024, 5:00 PM EST - 1 year ago

Kyntra Bio Earnings Call Transcript: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Kyntra Bio Quarterly report: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Kyntra Bio Earnings release: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Kyntra Bio Slides: Q3 2024

Nov 12, 2024, 4:05 PM EST - 1 year ago

FibroGen Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

FibroGen to Report Third Quarter 2024 Financial Results

Sep 10, 2024, 3:00 PM EDT - 2 years ago

Kyntra Bio Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Slides: Q2 2024

Jul 30, 2024, 4:07 PM EDT - 2 years ago

FibroGen to Report Second Quarter 2024 Financial Results

Jun 28, 2024, 8:00 AM EDT - 2 years ago

Kyntra Bio Registration statement: Registration Filing

Jun 10, 2024, 10:00 AM EDT - 2 years ago

Kyntra Bio Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 3, 2024, 4:05 PM EDT - 2 years ago

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

Jun 3, 2024, 4:02 PM EDT - 2 years ago

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

May 23, 2024, 5:05 PM EDT - 2 years ago

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology

May 20, 2024, 1:30 PM EDT - 2 years ago

Kyntra Bio Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 7, 2024, 7:00 AM EDT - 2 years ago

FibroGen to Participate in Upcoming Investor Conferences

May 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Earnings Call Transcript: Q1 2024

May 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Quarterly report: Q1 2024

May 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Earnings release: Q1 2024

May 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Slides: Q1 2024

May 6, 2024, 4:02 PM EDT - 2 years ago

FibroGen Reports First Quarter 2024 Financial Results

Apr 29, 2024, 7:00 AM EDT - 2 years ago

FibroGen to Report First Quarter 2024 Financial Results

Apr 24, 2024, 4:02 PM EDT - 2 years ago

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Kyntra Bio Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Kyntra Bio Proxy statement: Proxy Filing

Apr 9, 2024, 3:00 PM EDT - 2 years ago

Kyntra Bio Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 9, 2024, 3:00 PM EDT - 2 years ago

Kyntra Bio Slides: 23rd Annual Needham Virtual Healthcare Conference

Apr 2, 2024, 5:46 PM EDT - 2 years ago

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

Mar 26, 2024, 7:00 AM EDT - 2 years ago

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

Mar 11, 2024, 7:00 AM EDT - 2 years ago

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Feb 26, 2024, 5:00 PM EST - 2 years ago

Kyntra Bio Earnings Call Transcript: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Kyntra Bio Annual report: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Kyntra Bio Earnings release: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Kyntra Bio Slides: Q4 2023

Feb 26, 2024, 4:18 PM EST - 2 years ago

FibroGen regains rights to anemia drug from AstraZeneca

AZN

Feb 26, 2024, 4:06 PM EST - 2 years ago

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 26, 2024, 4:05 PM EST - 2 years ago

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

Feb 20, 2024, 7:00 AM EST - 2 years ago

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

Feb 13, 2024, 10:30 AM EST - 2 years ago

Kyntra Bio Transcript: Study Update

Feb 5, 2024, 7:00 AM EST - 2 years ago

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

Jan 25, 2024, 7:00 AM EST - 2 years ago

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

Jan 10, 2024, 3:00 PM EST - 2 years ago

Kyntra Bio Slides: Corporate Presentation

Dec 9, 2023, 5:02 PM EST - 2 years ago

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

Nov 6, 2023, 5:00 PM EST - 3 years ago

Kyntra Bio Earnings Call Transcript: Q3 2023

Nov 6, 2023, 5:00 PM EST - 3 years ago

Kyntra Bio Quarterly report: Q3 2023

Nov 6, 2023, 5:00 PM EST - 3 years ago

Kyntra Bio Earnings release: Q3 2023

Nov 6, 2023, 5:00 PM EST - 3 years ago

Kyntra Bio Slides: Q3 2023

Nov 6, 2023, 4:01 PM EST - 3 years ago

FibroGen Reports Third Quarter 2023 Financial Results

Oct 23, 2023, 7:00 AM EDT - 3 years ago

FibroGen to Report Third Quarter 2023 Financial Results

ARKADIY_PAROVOZOV Aug. 19 at 11:34 AM

0 · Reply

ARKADIY_PAROVOZOV Aug. 18 at 9:50 AM

1 · Reply

MaxMiamiFl Aug. 16 at 9:48 PM

$KYNB is this crap ever going to recover.....or at least close to it.

0 · Reply

Estimize Aug. 13 at 3:01 PM

$KYNB reports after the close, Estimize Consensus +0.24 EPS and -0.10M Revs compared to WS http://www.estimize.com/kynb/fq2-2026?utm_conten

0 · Reply

ARKADIY_PAROVOZOV Aug. 13 at 1:29 PM

1 · Reply

ARKADIY_PAROVOZOV Aug. 12 at 9:38 AM

0 · Reply

ARKADIY_PAROVOZOV Aug. 12 at 9:38 AM

0 · Reply

Estimize Aug. 11 at 10:06 PM

Wall St is expecting -3.18 EPS for $KYNB Q2 [Reporting 08/13 AMC] http://www.estimize.com/intro/kynb?chart=historical&metric_name=eps&utm_c

0 · Reply

Estimize Aug. 11 at 8:03 PM

Wall St is expecting -3.33 EPS for $KYNB Q3 [Reporting 11/09 AMC] http://www.estimize.com/intro/kynb?chart=historical&metric_name=eps&utm_c

0 · Reply

ARKADIY_PAROVOZOV Aug. 11 at 2:57 PM

0 · Reply

ARKADIY_PAROVOZOV Aug. 10 at 12:55 PM

$KYNB Phase 3 Roxadustat trial in LR-MDS with high transfusion burden (NCT07722988) is listed on ClinicalTrials.Veeva. Sponsored by Kyntra Bio, ~201 patients planned, status: begins enrollment in ~7 months. https://ctv.veeva.com/study/a-study-to-investigate-the-efficacy-and-safety-of-roxadustat-fg-4592-for-treating-anemia-in-partic

1 · Reply

ARKADIY_PAROVOZOV Aug. 10 at 12:52 PM

$KYNB Kyntra Bio’s Q2 2026 financial results are scheduled for Thursday, August 13 (after market close). Conference call at 5:00 PM ET. https://investor.kyntrabio.com/news-releases/news-release-details/kyntra-bio-report-second-quarter-2026-financial-results

1 · Reply

mjtwins16 Aug. 6 at 7:03 PM

$KYNB https://clinicaltrials.gov/study/NCT07722988

1 · Reply

MaxMiamiFl Aug. 5 at 1:17 PM

$KYNB this think should be at least 100m MC. Lets not forget it was close to a billion market cap...at one point.

0 · Reply

ARKADIY_PAROVOZOV Aug. 5 at 12:49 PM

$KYNB Positive preclinical data (Aug 3, 2026): a new nanoparticle formulation of Roxadustat significantly improved antifibrotic efficacy and reduced systemic exposure in a pulmonary fibrosis model compared with free drug. Supports broader potential of Roxadustat beyond anemia. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1921860/full

0 · Reply

RespectedElder Aug. 3 at 4:21 PM

$KYNB hiring senior medical director. “Demonstrated experience in oncology drug development with expertise in solid tumors.” So the oncology trial seems to be on its way. That leaves Roxadustat open. Partnership in the works? https://ats.rippling.com/kyntrabio/jobs/f6f02f81-1395-40e1-bb92-d97699b54334

1 · Reply

ARKADIY_PAROVOZOV Aug. 3 at 7:50 AM

$KYNB Astellas is running a Phase 3 study of Roxadustat for anemia in children and teenagers with chronic kidney disease (NCT05970172). The trial is currently recruiting and evaluates efficacy and safety in patients aged 2–17 years. https://www.humanexasignals.com/signals/roxadustat-study-for-anemia-in-children-with-chronic-kidney-disease-initiated-by

1 · Reply

ARKADIY_PAROVOZOV Jul. 31 at 8:46 AM

$KYNB New retrospective study (published July 30, 2026) in British Journal of Clinical Pharmacology shows Roxadustat was more effective than rhEPO for post-transplant anemia in kidney transplant recipients at 6 months. Response rate: 94.4% vs 78.1%. Note: significant drug–drug interaction with tacrolimus (increased exposure). https://doi.org/10.1002/bcp.70713

0 · Reply

ARKADIY_PAROVOZOV Jul. 28 at 1:49 PM

$KYNB 🚨 New MDPI Study (2026): Independent research confirms that HIF-1α stabilization—the exact mechanism behind Roxadustat (Evrenzo)—is a highly promising strategy for organ protection in type 2 diabetes. This further validates the molecule's robust science and its massive potential to expand into massive new markets far beyond CKD anemia. https://www.mdpi.com/2079-7737/15/15/1241

2 · Reply

MaxMiamiFl Jul. 27 at 1:35 PM

$KYNB this s...t has died. No news, no rumors...nothing but red.

0 · Reply

MaxMiamiFl Jul. 23 at 12:50 PM

$KYNB

0 · Reply

Estimize Jul. 20 at 11:01 AM

Wall St is expecting -3.18 EPS for $KYNB Q2 [Reporting 08/10 AMC] http://www.estimize.com/intro/kynb?chart=historical&metric_name=eps&utm_c

0 · Reply

Market Cap	27.57M
Revenue (ttm)	6.44M
Net Income (ttm)	183.45M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	2,848.60%
Debt to Equity Ratio	0.00

Volume	13,700
Avg Vol	20,724
Day's Range	N/A - N/A
Shares Out	4.05M
Stochastic %K	33%
Beta	1.02
Analysts	Strong Sell
Price Target	$36.00